MON-312 The Effects of Cabergoline in Pre-Surgical and Recurrence Periods of Cushing’s Disease Patients

BACKGROUND: Dopaminergic agonist cabergoline (CAB) has been used in pharmacological treatment of Cushing’s disease (CD). The effect is attributed to the frequent expression of subtype 2 dopamine receptor in corticotropic tumors. However, in vivo studies demonstrated normalization of urinary cortisol...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Main Authors: Pereira, Ana Julia Garcia, Andrade, Natália Xavier S, Musolino, Nina Rosa de Castro, Cescato, Valter Angelo Sperling, da Silva, Gilberto Ochman, Fragoso, Maria Candida Barisson Villares, Bronstein, Marcello Delano, Machado, Marcio Carlos
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Neuroendocrinology and Pituitary
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209226/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.572
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares